Refine
Has Fulltext
- yes (17)
Is part of the Bibliography
- yes (17)
Year of publication
Document Type
- Journal article (16)
- Doctoral Thesis (1)
Keywords
- multiple sclerosis (5)
- Myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) (3)
- Neuromyelitis optica spectrum disorders (NMOSD) (3)
- Optic neuritis (3)
- Autoantibodies (2)
- Cerebrospinal fluid (2)
- Longitudinally extensive transverse myelitis (LETM) (2)
- MS (2)
- Multiple sclerosis (2)
- Antibody index (1)
- Aquaporin-4 antibodies (AQP4-Ig, NMO-IgG)G (1)
- Aquaporin-4 antibodies (AQP4-IgG) (1)
- Aquaporin-4 antibodies (AQP4-IgG, NMO-IgG) (1)
- Ataxia (1)
- Azathioprine (1)
- Barkhof criteria (1)
- Biomarker (1)
- Brainstem encephalitis (1)
- CBP (1)
- CSF (1)
- CXCL5 (1)
- CXCL8 (1)
- CXCR2 (1)
- Cell-based assays (1)
- Cerebellitis (1)
- Devic syndrome (1)
- Devic’s syndrome (1)
- Diplopia Internuclear ophthalmoplegia (INO) (1)
- Electrophysiology (1)
- Evoked potentials (1)
- Facial nerve palsy (1)
- Gehirn (1)
- Glatiramer acetate (1)
- Hearing loss (1)
- IL-22 binding protein isoform (1)
- IL22RA2 (1)
- IPND criteria (1)
- Infections (1)
- Interferon beta (1)
- International consensus diagnostic criteria for neuromyelitis optica spectrum disorders (1)
- Intractable nausea and vomiting (1)
- Longitudinally extensive transverse myelitis (1)
- Lysosomal storage disease (1)
- MOG-IgG (1)
- MRI criteria (1)
- Magnetic resonance imaging (1)
- McDonald criteria (1)
- Medizin (1)
- Methotrexate (1)
- Myelin oligodendrocyte glycoprotein (MOG) antibodies (1)
- Myelitis (1)
- NF-AT (1)
- NF-\(\kappa\)B (1)
- NFAT (1)
- NMO-IgG (1)
- Natalizumab (1)
- Neurodegeneration (1)
- Neuromyelitis optica (NMO) (1)
- Neuromyelitis optica antibodies (NMO-IgG) (1)
- Neuronal ceroid lipofuscinosis (1)
- OCB (1)
- Ofatumumab (1)
- Oligoclonal bands (1)
- Optical coherence tomography (1)
- Outcome (1)
- Pregnancy (1)
- Rac (1)
- Raf (1)
- Respiratory insufficiency (1)
- Retinal degeneration (1)
- Rhombencephalitis (1)
- Rituximab (1)
- SB332235 (1)
- TAD-A (1)
- Therapy (1)
- Transverse Myelitis (1)
- Transverse myelitis (1)
- Treatment (1)
- Ureaplasma species (1)
- VCAM-1 (1)
- Vaccination (1)
- Wingerchuk criteria 2006 and 2015 (1)
- acid sphingomyelinase (1)
- antidepressants (1)
- aquaporin-4 antibodies (AQP4-IgG) (1)
- association (1)
- atypical chemokine receptor 3 (1)
- autoimmune (1)
- barrier integrity (1)
- biomarker (1)
- blood-brain barrier (1)
- blood–brain barrier (1)
- cell adhesion (1)
- cerebrospinal fluid (1)
- conversion (1)
- criteria (1)
- differential diagnosis (1)
- dimethyl fumarate (1)
- drug (1)
- endothelial cells (1)
- gene (1)
- genetics (1)
- human brain microvascular endothelial cells (1)
- human cerebral endothelial cells (1)
- interleukin-8 (1)
- linkage (1)
- major depression (1)
- meningitis (1)
- monomethyl fumarate (1)
- multiple sklerosis (1)
- mutation (1)
- nervous-system (1)
- neuroinflammation (1)
- neuromyelitis optica (1)
- neuromyelitis optica spectrum disorders (NMOSD) (1)
- optic neuritis (1)
- optical coherence tomography (1)
- p300 (1)
- p38 mitogen-activated protein kinase (1)
- plasminogen (1)
- potent inducer (1)
- proteins (1)
- regulatory T cells (1)
- retinal neuro-axonal damage (1)
- serum (1)
- signal peptide (1)
- sphingolipids (1)
- visual acuity (1)
- visual evoked potentials (1)
Institute
- Neurologische Klinik und Poliklinik (13)
- Pathologisches Institut (3)
- Institut für Virologie und Immunbiologie (2)
- Kinderklinik und Poliklinik (2)
- Augenklinik und Poliklinik (1)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (1)
- Institut für Hygiene und Mikrobiologie (1)
- Institut für Klinische Neurobiologie (1)
- Institut für Organische Chemie (1)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (1)
Background
A subset of patients with neuromyelitis optica spectrum disorders (NMOSD) has been shown to be seropositive for myelin oligodendrocyte glycoprotein antibodies (MOG-IgG).
Objective
To describe the epidemiological, clinical, radiological, cerebrospinal fluid (CSF), and electrophysiological features of a large cohort of MOG-IgG-positive patients with optic neuritis (ON) and/or myelitis (n = 50) as well as attack and long-term treatment outcomes.
Methods
Retrospective multicenter study.
Results
The sex ratio was 1:2.8 (m:f). Median age at onset was 31 years (range 6-70). The disease followed a multiphasic course in 80% (median time-to-first-relapse 5 months; annualized relapse rate 0.92) and resulted in significant disability in 40% (mean follow-up 75 ± 46.5 months), with severe visual impairment or functional blindness (36%) and markedly impaired ambulation due to paresis or ataxia (25%) as the most common long-term sequelae. Functional blindness in one or both eyes was noted during at least one ON attack in around 70%. Perioptic enhancement was present in several patients. Besides acute tetra-/paraparesis, dysesthesia and pain were common in acute myelitis (70%). Longitudinally extensive spinal cord lesions were frequent, but short lesions occurred at least once in 44%. Fourty-one percent had a history of simultaneous ON and myelitis. Clinical or radiological involvement of the brain, brainstem, or cerebellum was present in 50%; extra-opticospinal symptoms included intractable nausea and vomiting and respiratory insufficiency (fatal in one). CSF pleocytosis (partly neutrophilic) was present in 70%, oligoclonal bands in only 13%, and blood-CSF-barrier dysfunction in 32%. Intravenous methylprednisolone (IVMP) and long-term immunosuppression were often effective; however, treatment failure leading to rapid accumulation of disability was noted in many patients as well as flare-ups after steroid withdrawal. Full recovery was achieved by plasma exchange in some cases, including after IVMP failure. Breakthrough attacks under azathioprine were linked to the drug-specific latency period and a lack of cotreatment with oral steroids. Methotrexate was effective in 5/6 patients. Interferon-beta was associated with ongoing or increasing disease activity. Rituximab and ofatumumab were effective in some patients. However, treatment with rituximab was followed by early relapses in several cases; end-of-dose relapses occurred 9-12 months after the first infusion. Coexisting autoimmunity was rare (9%). Wingerchuk’s 2006 and 2015 criteria for NMO(SD) and Barkhof and McDonald criteria for multiple sclerosis (MS) were met by 28%, 32%, 15%, 33%, respectively; MS had been suspected in 36%. Disease onset or relapses were preceded by infection, vaccination, or pregnancy/delivery in several cases.
Conclusion
Our findings from a predominantly Caucasian cohort strongly argue against the concept of MOG-IgG denoting a mild and usually monophasic variant of NMOSD. The predominantly relapsing and often severe disease course and the short median time to second attack support the use of prophylactic long-term treatments in patients with MOG-IgG-positive ON and/or myelitis.